International Eczema Council

03/26/2026

❗ Throwback Thursday ❗

Gemini said
Prurigo Nodularis (PN) is a distinct neuroimmune disease defined by chronic itch, dermal fibrosis, and neural hypertrophy, often presenting as firm nodules in scratch-accessible areas. Unlike atopic dermatitis, PN is strongly associated with systemic comorbidities like metabolic disorders and depression, requiring a multidisciplinary approach. Breakthrough biologics targeting type 2 inflammation and IL-31, such as dupilumab and nemolizumab, have revolutionized care by rapidly breaking the itch-scratch cycle and clearing lesions.

Prurigo Nodularis at AAD 2023 | March 16, 2023 Ernest N. Morial Convention Center, New Orleans, LA, USA

03/25/2026

The International Eczema Council (IEC) is pleased to feature Arbie Sofia Merilleno, MD, our 2024 Canadian Research Fellow. Dr. Merilleno’s work is a vital part of our mission to advance the understanding and treatment of atopic dermatitis through dedicated research.

Read her profile: https://www.eczemacouncil.org/2024-fellow--arbie-sofia-merilleno--md-

03/23/2026

Join the International Eczema Council in Chicago on Wednesday, May 13, 2026, for our SID 2026 symposium, "The Infection Question in AD: What’s Driving Risk Today?". Co-chaired by Dr. April W. Armstrong and Dr. Patrick M. Brunner, this session at the Hilton Chicago runs from 8:00 AM to 12:00 PM CST and will examine the latest factors influencing infection risks in atopic dermatitis.

Registration: https://www.eczemacouncil.org/index.php?option=com_jevents&task=icalevent.detail&evid=70

03/19/2026

❗ Throwback Thursday ❗

The International Eczema Council (IEC) recently hosted a global symposium detailing atopic dermatitis as a systemic inflammatory disease that requires highly personalized management. Experts discussed the necessity of adapting diagnostic criteria for diverse populations, noting that clinical presentations often vary by age and ethnicity, such as the unique morphologies seen in skin of color.

The session also reviewed advancements in targeted therapies, including biologics and JAK inhibitors, while emphasizing the importance of overcoming therapeutic inertia to improve long-term patient outcomes and manage infection risks.

New Developments in Atopic Dermatitis and Implications for the Atopic March at AAAAI 2023 | February 23, 2023, 1:00 - 5:00 PM Central Time Henry B. Gonzalez ...

03/18/2026

IEC extends its sincere gratitude to Galderma for their generous sponsorship for the upcoming 2026 events.

Your support plays a vital role in advancing our mission and driving innovation within our community. Thank you for partnering with us in this important journey.

03/16/2026

The International Eczema Council (IEC) is pleased to introduce Carlos Eduardo Forero Ángel, MD, as our 2025 International Research Fellow. As a dedicated dermatologist, Dr. Forero Ángel is focused on advancing our understanding of atopic dermatitis through rigorous scientific inquiry and clinical research.

His work represents the IEC's ongoing commitment to fostering the next generation of leaders who are dedicated to solving the complexities of eczema.

Read his Profile: https://www.eczemacouncil.org/2025-fellow--carlos-eduardo-forero--ngel--md

Watch his Fellowship Story: https://www.youtube.com/watch?v=eLuJR747Nlg

03/12/2026

❗ Throwback Thursday ❗

The International Eczema Council (IEC) recently highlighted how single-cell and spatial transcriptomics are transforming our understanding of atopic dermatitis (AD). These technologies have revealed that fibroblasts play a critical, underappreciated role in driving Th2 inflammation and skin barrier disruption. Furthermore, the application of minimally invasive "tape stripping" now allows researchers to track molecular biomarkers in both infants and adults, facilitating longitudinal monitoring and more personalized therapeutic strategies.

ESDR 2022 | IEC Symposium Single Cell Technologies Application to Atopic Eczema

03/11/2026

The International Eczema Council (IEC) is proud to highlight the impactful work of our 2022 US Clinical Fellow, Caroline Marie Thérèse Mann, MD. Dr. Mann’s dedication to advancing the field of dermatology and improving patient outcomes remains a cornerstone of our fellowship program's mission.

Read her full profile: https://www.eczemacouncil.org/2022-fellow--caroline-marie-th-r-se-mann--md

Watch her Fellowship story: https://www.youtube.com/shorts/2gSOOPvdPVk

03/09/2026

Join the International Eczema Council (IEC) and the International Psoriasis Council (IPC) for a special AAD Global Education Day Session in Denver! We’ll be diving deep into complex cases where "treatments flip the script."

Save the date and learn more here: https://www.eczemacouncil.org/index.php?option=com_jevents&task=icalevent.detail&evid=69

03/05/2026

❗ Throwback Thursday ❗

The International Eczema Council (IEC) recently held a symposium in Milan on tailoring atopic dermatitis (AD) treatments to diverse populations. AD presents differently based on age and ethnicity; for example, infants primarily show Th2 activation, while adults exhibit Th1 and Th22 pathways.

Research also shows higher AD prevalence in skin of color populations, often featuring unique clinical signs like prominent papules. With the rise of systemic treatments like biologics and JAK inhibitors, the IEC emphasizes the need for precision medicine that accounts for a patient's specific genetic and demographic background.

EADV 2022 | Customizing the Treatment of Atopic Dermatitis for Diverse Populations

03/05/2026

Dear IEC Patients and Care Partners:

As part of a grant-supported initiative, the International Eczema Council invites your participation in a brief survey on atopic dermatitis (eczema). Research shows that patients and physicians often differ in how they interpret symptoms, define treatment goals, and assess impact. In partnership with Pediatric Dermatology Research Alliance (PeDRA) and Global Parents for Eczema Research (GPER), IEC is working to better align these perspectives—and your voice is essential.

If you are a U.S.-based patient with atopic dermatitis or a care partner to an adult or child who is, please consider completing the IEC Patient and Caregiver Survey – Aligning Perspectives on the Definition of Disease Activity Level and Remission. The survey takes just 15 minutes and is open through March 3.

This study aims to strengthen shared understanding of disease control, refine clinical endpoints, and advance patient-centered eczema care worldwide.

Thank you for helping move eczema care forward!

https://lnkd.in/eCjqnuqV